Regent Enterp. (512624)

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at a sharp discount to book value: P/B of 0.39 with book value ₹13.26 versus price ₹5.19.
• P/E of 4.91 and PEG of 0.01 are optically cheap, though the growth denominator is low-base.
• Piotroski F-Score of 7/9 signals improving financial health across margins, leverage, and efficiency.
• Sales growth of 21.38% and ROCE of 13.59% indicate some business momentum and capital productivity.
• Latest quarter sales of ₹272 Cr show meaningful distribution scale despite the tiny market cap.

Concerns

• Net margin is extremely thin: ₹2 Cr profit on ₹272 Cr sales, about 0.7%, leaving little buffer.
• 1,000% profit growth is off a very low base and is not a reliable sign of sustainable compounding.
• Insufficient disclosures: no debt/equity ratio, no promoter holding, and zero dividend create governance and transparency risks.
• Trading and distribution businesses usually lack a durable moat, and the stock’s price near its 52-week low suggests market skepticism.

AI Analysis

At ₹5.19, Regent Enterp. is a Rs 17 crore micro-cap trading and distribution business. On the surface, the numbers look intriguing: a P/E of 4.91, a P/B of 0.39, and book value of ₹13.26 against a price of ₹5.19. A Graham investor naturally pauses when a stock sells at less than half book value. But in trading, book value may comprise assets whose quality I need to verify before calling it a bargain. One bad season can erode those assets. The earnings story is less clean. Profit growth of 1000% sounds spectacular—so does the PEG of 0.01—but the latest quarter shows net profit of only ₹2 Cr on sales of ₹272 Cr, a margin under 1%. That is a low-margin distribution business, with little inherent pricing power or durable moat. Sales growth of 21.38% is nice, but if margins remain razor-thin, scale does not necessarily create shareholder value. The Piotroski score of 7/9 is encouraging and suggests improving profitability and financial health. ROCE of 13.59% and ROE of 10.02% are decent but not outstanding. There is no dividend, no promoter holding data, and no debt-equity ratio disclosed—uncomfortable gaps for a minority shareholder. The stock trades near the bottom of its 52-week range, which tells me the market has reservations. This is an asset play, not a consistent compounder. I would buy only after checking that the book value is real and the earning power isn't fading. At this price, you get a margin of safety if assets hold; otherwise, you own a value trap.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer